One sentence summary: In vivo bioluminescence imaging revealed that probiotic Lactobacillus brevis KB290 inhibited the proliferation of Citrobacter rodentium, an enteric bacterial pathogen, especially in the early stage of murine infection. Editor: Célia Ferreira ABSTRACT Bioluminescent imaging (BLI) has become a useful tool for monitoring bacterial infections in real time. Citrobacter rodentium and its BLI are widely used as a murine model of enteropathogenic and enterohaemorrhagic Escherichia coli infection. In this study, we evaluated the protective effects of the probiotic Lactobacillus brevis KB290 against C. rodentium infection by the BLI approach. First, we examined several solutions for making the suspension of bioluminescent C. rodentium for an oral inoculation to establish a stable intestinal infection. Three percent NaHCO 3 solution was found to be the best. Subsequently, mice were orally administered KB290 once daily for 7 days before inoculation with bioluminescent C. rodentium and for 8 days after infection. The bioluminescence intensity of mice fed with KB290 was significantly lower than that of unfed mice on days 1-3 after infection. The mRNA levels of tumour necrosis factor-α and interferon-γ in the distal colon from KB290-fed mice were shown to be significantly higher than those from unfed mice on day 3 after infection. The results suggested that KB290 intake partially inhibited the proliferation of C. rodentium, especially in the early stages of infection, viathe moderate enhancement of tumour necrosis factor-α and interferon-γ production in the colon.
INTRODUCTION
Enteric bacterial pathogens, such as enteropathogenic Escherichia coli (EPEC) and enterohaemorrhagic E. coli (EHEC), cause severe diarrhoea, especially in children (Clarke et al. 2003) . These pathogens intimately adhere to caecal and colonic epithelial cells and disrupt cellular structures through the formation of attaching and effacing lesions (Simmons et al. 2002) . Citrobacter rodentium, a mouse enteric pathogen, is widely used as a murine model of EPEC and EHEC infection (Mundy et al. 2005) . Similar to EPEC and EHEC, it has been reported that C. rodentium possesses the locus of enterocyte effacement pathogenicity island encoding a type III secretion system (Wiles et al. 2006) .
Bioluminescent imaging (BLI) has recently been used for monitoring bacterial infections in real time. Various species of Gram-negative bacteria, including C. rodentium, have been rendered luminescent (Wiles et al. 2006; Riedel et al. 2007 ). The system using C. rodentium combined with BLI detection has become useful to investigate the protective effect of probiotics against C. rodentium infection as a murine model of EPEC and EHEC (Collins et al. 2012) .
Lactobacillus brevis KB290 (KB290) is a probiotic lactic acid bacterium (LAB) isolated from 'Suguki', a traditional pickle produced in Kyoto, Japan. KB290 has been reported to be safe for human consumption and improve gut health (Nobuta et al. 2009 ). In addition, it has been revealed that orally administered KB290 enhances interferon (IFN)-α production in humans (Kishi et al. 1996) and increases the cell-mediated cytotoxic activity of splenocytes in mice (Fukui et al. 2013 (Fukui et al. , 2014 . IFN-α and cytotoxic activity play an important role in innate immune responses against viral infection (Terunuma et al. 2008; Matzinger et al. 2011) . Indeed, we have reported that KB290 intake alleviates the clinical symptoms induced by influenza virus infection in mice (Waki et al. 2014b) and reduces the incidence of influenza in schoolchildren (Waki et al. 2014a) . In enteric infections, however, the protective effect of KB290 against bacterial pathogens remains to be clarified, although other LABs have been shown to be preventive (Castillo, Perdigón and de Moreno de Leblanc 2011; Rodrigues et al. 2012) . The aim of this study is to evaluate the protective effect of KB290 against gastrointestinal infections with a bioluminescent enteric bacterium such as C. rodentium in a murine model using the in vivo BLI method.
MATERIALS AND METHODS

Ethics statement
All animal experiments conformed to the guidelines of the Animal Research Committee of the University of Shizuoka, and all efforts were made to minimise animal suffering. Experimental procedures were approved by the Animal Research Committee of the University of Shizuoka (Approval # 135006).
Mice
Five-week-old and specific pathogen-free female C57BL/6 mice (body weight 17.8 ± 0.61 g) were purchased from CLEA Japan, Inc. (Tokyo, Japan) and were housed in a temperature-controlled environment (23 ± 2
• C, humidity 50 ± 10%) under a 12-h dark:12-h light cycle with food and water available ad libitum. We used female C57BL/6 mice which were frequently used for experimental infection with Citrobacter rodentium (Wiles et al. 2006; Rodrigues et al. 2012; Hall et al. 2013) , because male C57BL/6 mice tend to fight and cause injury each other.
Preparation of Citrobacter rodentium ICC169::p16lux for oral inoculation
Citrobacter rodentium ICC169::p16lux is a luminescent bacterium derived from C. rodentium ICC169 and was kindly provided by Drs Cormac G. Gahan and Pat G. Casey at the University College Cork, Ireland (Riedel et al. 2007 ). Bioluminescent C. rodentium was cultured with Luria-Bertani (LB) broth supplemented with 250 μg ml −1 erythromycin (Wako Pure Chemical Industries, Ltd., Osaka, Japan) overnight at 37
• C, and 2% of overnight culture was further cultured for 3 h with fresh LB broth supplemented with 250 μg ml −1 erythromycin at 37
• C. The bacterial culture was then centrifuged at 2500 × g for 10 min at 4
• C and the supernatant was removed. The bacterial precipitate was washed twice with phosphate-buffered saline (PBS) and adjusted to 2 × 10 10 colonyforming units (CFU) ml −1 with PBS or 10× PBS (2.0 g potassium dihydrogenphosphate, 0.2 g potassium chloride, 11.5 g disodium hydrogenphosphate and 8.0 g sodium chloride in 1.0 L of distilled water) and used for oral inoculation. To make the bacterial suspension with 3% (w/v) NaHCO 3 (Wako Pure Chemical Industries, Ltd.) solution for inoculation, the bacterial cells were washed twice and adjusted to 4 × 10 10 CFU ml −1 with PBS, and mixed with an equal volume of a solution with 6% (w/v) NaHCO 3 solution just before oral inoculation of mice.
Preparation of KB290 for oral administration
KB290 was deposited as strain Lactobacillus brevis JCM 17312 in the Japan Collection of Microorganisms. KB290 was grown aerobically in de Man-Rogosa-Sharpe broth (Merck Ltd., Tokyo, Japan) overnight at 30
• C. The bacterial culture was centrifuged at 2500 × g for 10 min at 4
• C, and then the supernatant was removed. The bacterial precipitate was washed twice and adjusted to 1 × 10 10 CFU ml −1 with PBS and used for oral administration.
Evaluation of three solutions to suspend Citrobacter rodentium ICC169::p16lux for oral inoculation
Mice were habituated for 1 week and then orally inoculated with 2 × 10 9 CFU 100 μl −1 of C. rodentium ICC169::p16lux. To protect the viability of C. rodentium in mouse stomachs (i.e. to decrease the influence of gastric acid), PBS, 10× PBS and 3% NaHCO 3 were examined to select which one was the best for the preparation of a bacterial suspension as described above. After inoculation with the three bacterial suspensions, we immediately analysed the presence of viable bacteria by bioluminescence in the abdomens of mice by BLI using the in vivo imaging system (IVIS) (Xenogen Co., Alameda, CA, USA) under isoflurane (Mylan, Tokyo, Japan) anaesthesia. The intensity of luminescent emission (photons s −1 cm −2 ) was quantified over 1 min in the region of interest of murine abdomen using the Living Image Software (Xenogen Co).
Evaluation of protective effects of KB290 to Citrobacter rodentium infection
The experimental design is shown in Fig. 1 . Mice were divided into three groups: a group of uninfected mice (uninfected), a group of C. rodentium-infected mice (infected) and a group of C. rodentium-infected mice with KB290 intake (KB290 + infected). Mice in each of the uninfected and infected groups were orally administered 100 μl of PBS by gavage daily for 10 or 15 days. Mice in the KB290 + infected group were orally given KB290 in 100 μl of PBS by gavage daily for the same period (1 × 10 9 CFU day −1 ). After treatment with PBS or KB290 for 7 days, mice in Figure 1 . Experimental design. Mice in the uninfected and infected groups were orally administered 100 μl of PBS by gavage daily for 10 or 15 days, while mice in the KB290 + infected group were orally given KB290 in 100 μl of PBS by gavage daily for the same period (dotted lines). Mice in the infected and KB290 + infected groups were inoculated orally with C. rodentium ICC169::p16lux, while mice in the uninfected group were administered 100 μl of 3% NaHCO3 alone as a sham treatment (open triangle). Then, mice in the infected and KB290 + infected groups were daily analysed for the presence of bioluminescent bacteria under isoflurane anaesthesia by BLI using IVIS (solid line). On day 3 or 8 after infection, mice were euthanised by cervical dislocation after isoflurane anaesthesia and the colonic tissue was collected (filled triangle).
infected and KB290 + infected groups were inoculated orally with 2 × 10 9 CFU 100 μl −1 of C. rodentium ICC169::p16lux, which was suspended in 3% NaHCO 3 . Mice in the uninfected group were administered 100 μl of 3% NaHCO 3 alone as a sham treatment. Then, mice in the infected and KB290 + infected groups were analysed daily for the presence of bioluminescent bacteria under isoflurane anaesthesia by BLI using IVIS, and the bacterial emission was quantified in the region of interest of the murine abdomen. Although mouse body weight and infection severity were monitored for the consideration of a humane endpoint, all animal experiments were safely terminated on day 8 after infection. On day 3 or 8 after infection, mice were euthanised by cervical dislocation after isoflurane anaesthesia and the entire colonic tissue was collected and a part of the distal colon (1 cm) was stored in RNAlater solution (Ambion Inc., Austin, TX, USA) at −80 • C to analyse the mRNA expression.
Analysis of mRNA expression of inflammatory cytokines by quantitative reverse-transcription polymerase chain reaction
Total RNA was isolated using NucleoSpin RNA II (MACHEREY-NAGEL GmbH & Co. KG, Düren, Germany) and complementary DNA was synthesised from 0.5 μg total RNA using PrimeScript RT reagent kit (Takara Bio Inc., Shiga, Japan), according to the manufacturer's instructions. The levels of mRNA transcripts for β-actin, tumour necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-12p40 and IFN-γ (Table 1) were measured by quantitative RTpolymerase chain reaction (qPCR) using a Thermal Cycler Dice Real Time System (Takara Bio Inc.). For relative quantitation, the cytokine expression level was normalised using the expression of the housekeeping gene β-actin, and the 2 − Ct method was used to calculate the relative expression level of the cytokines among uninfected, infected and KB290 + infected groups (Livak and Schmittgen 2001) .
RESULTS
Selection of the solution to suspend Citrobacter rodentium ICC169::p16lux prior to oral inoculation
Generally, PBS is used to resuspend C. rodentium after centrifugation of bacterial cultures for oral inoculation in mice. However, in our preliminary BLI analysis with PBS, we found that some C57BL/6 mice were not stably infected with C. rodentium ICC169::p16lux. The reason for such unstable infection was thought to be owing to the inactivation of the bacteria by mouse gastric acid. Therefore, we first examined three solutions (PBS, 10× PBS and 3% NaHCO 3 ) to select which one is the best as a bacterial suspension for oral inoculation to decrease the influence of gastric acid. Notably, strong luminescence emissions were obtained in all mice infected with C. rodentium ICC169::p16lux suspended in 3% NaHCO 3 , while the luminescence emissions in C. rodentium-infected mice with PBS, as well as 10× PBS, used as inoculum solutions were notably weaker ( Fig. 2A) . The mean value of the luminescent emission intensity in 3% NaHCO 3 tended to be higher than the two other solutions tested (Fig. 2B) . Therefore, 3% NaHCO 3 solution was used for the following experiments.
Evaluation of protective effect of KB290 against
Citrobacter rodentium infection KB290 is a probiotic LAB commercially available in beverages in Japan. For the evaluation of the protective effect of KB290 against enteric pathogenic bacteria, mice were orally administered KB290 for 7 days before C. rodentium inoculation and for 8 days after inoculation (total 15 days). On days 1, 2 and 3 after infection in the early stage of infection, the luminescence intensity of mouse abdomens in KB290 + infected group was significantly lower than that of the infected group (Fig. 3) . The same trend continued throughout the experiment, and even in the late stage of infection the luminescence intensity of KB290 + infected group tended to be lower than that of infected group The quantitative analysis of bioluminescence emission in the region of interest of the murine abdomen. Data represent the means of luminescence intensity from the respective mouse group; n = 3 (PBS group), except for a luminescent-undetected mouse (the rightmost one of the PBS group in Fig. 2A) , n = 5 (10× PBS group) or n = 6 (3% NaHCO3 group). were administered PBS as a control (infected group). After treatment with PBS or KB290 for 7 days, mice were inoculated orally with 2 × 10 9 CFU of C. rodentium ICC169::p16lux. Then, mice were analysed daily for the presence of bioluminescent bacteria under isoflurane anaesthesia by IVIS, and the bacterial emission (photon s −1 cm 2 ) was quantified in the region of interest of the murine abdomen. * * P < 0.01, * P < 0.05, by Mann-Whitney U test; n = 5-6 mice in each group.
on days 6 and 8 after infection (P < 0.1). Furthermore, the body weight changes in mice were not significant between the experimental groups after infection (data not shown). Previous studies showed that significant changes in body weight of wild-type C57BL/6 mice were not observed after C. rodentium infection (Shiomi et al. 2010; Alipour et al. 2013; Su et al. 2014 ), supporting our results described above.
Analysis of mRNA expression of inflammatory cytokines in the distal colon
We next analysed the mRNA expression of inflammatory cytokines to explore the protective mechanism of KB290 against C. rodentium infection. The expression levels of TNF-α, IL-1β, IL-6, IL-12p40 and IFN-γ were measured by qPCR in the distal colon, one of the target organs of C. rodentium infection in mice. Notably, the mRNA expression levels of TNF-α and IFN-γ in the distal colon in the KB290 + infected group were significantly higher than those in other groups on day 3 after inoculation in the early stage of infection, while on day 8 after inoculation in the late stage of infection, IFN-γ level in KB290 + infected group tended to be higher than that in infected group (Fig. 4) . The three remaining cytokines were not markedly changed at the mRNA level in either the early stage (on day 3) or late stage (on days 8) of infection. The results suggest that the moderate upregulation of the expression levels of TNF-α and IFN-γ might be associated with the protective effect of KB290, especially in the early stage of infection.
DISCUSSION
In this study, oral inoculation with suspensions of Citrobacter rodentium in 3% NaHCO 3 solution was used to generate a stable infection model. KB290 intake was found to significantly inhibit the proliferation of C. rodentium in the early stage of infection by BLI analysis. We also observed the simultaneous enhancement of expression of TNF-α and IFN-γ in the colon. Because it is well known that the expression of inflammatory cytokines (including TNF-α and IFN-γ ) is induced by C. rodentium infection (Simmons et al. 2002; Baker et al. 2012) , the increase of expression of these cytokines is often considered a marker of the severity of the infection, and some LAB strains have been reported to suppress that expression (Rodrigues et al. 2012) . However, such proinflammatory cytokines are also known to be essential for the early innate immune responses to C. rodentium infection in the colon. Gonçalves et al. (2001) have reported that, after C. rodentium infection, TNFRp55-knockout mice showed increases in bacterial burden and the severity of mucosal hyperplasia in the colon, suggesting that TNF-α plays a role in controlling the bacterial colonisation on the surface of the gut epithelium by the regulation of innate immunity. Furthermore, it has also been reported that IFN-γ -deficient mice were more susceptible to oral infection with C. rodentium than wild-type C57BL/6 mice (Simmons et al. 2002) . These reports support the two effects of KB290 observed in the early stage of infection, specifically the inhibition of intestinal C. rodentium proliferation and the augmentation of colonic TNF-α and IFN-γ expression. Previously, we showed that orally administered KB290 enhanced cell-mediated cytotoxic activity, possibly by the activation of natural killer cells and/or CD8 + cytotoxic T cells in mice (Fukui et al. 2013 (Fukui et al. , 2014 . Natural killer cells are known to increase production of TNF-α and IFN-γ during C. rodentium infections and to be essential for initial clearance of the bacteria (Reid-Yu, Small and Coombes 2013). Such observations suggest that orally administered KB290 would allow the enhancement of the immune system to respond quickly to intestinal C. rodentium infections, supporting the potentially preventive effects of KB290 intake against the infection in this study.
Many strains of LABs have been reported to show protective effects against C. rodentium infection (Chen et al. 2005; Gareau et al. 2010) . However, there are fewer studies of immune responses and the protective effect of LABs in the early stage of infection. In this study, on day 3 there was no significant difference in TNF-α expression between the uninfected and infected groups, indicating that C. rodentium infection alone would not induce TNF-α production in the early stage of infection. Most interestingly, KB290 intake significantly enhanced the TNF-α and IFN-γ production in the colon and inhibited the proliferation of C. rodentium at this stage. The results suggest that the induction of proinflammatory cytokines by KB290 intake would possibly contribute to the protective effects against C. rodentium infection in the early stage. In contrast, on day 8, the TNF-α expression in the infected group and the KB290 + infected group tended to be upregulated. The induction of TNF-α expression in the late stage of infection could be owing to the proliferation of C. rodentium itself in the colon and lead to the progression of colonic inflammation. Indeed, the number of C. rodentium increased gradually in the late stages of infection in both infected and KB290 + infected groups (Fig. 3) . As far as we know, this study for the first time suggests that the enhancement of colonic inflammatory cytokines in the early stage of C. rodentium infection is associated with the protective effect of a certain LAB against the infection. Because we are able to visualise the proliferation of C. rodentium and monitor infection repeatedly in living mice by BLI, the best time point to evaluate the preventive mechanisms could be determined.
In the late stage of infection, KB290 intake is likely to incompletely inhibit the proliferation of C. rodentium in the colon as shown in BLI analysis: i.e. C. rodentium proliferation in the KB290 + infected group tended to be lower, but not significantly, than that in the infected group. This might partly result from the high challenge dose of C. rodentium (2 × 10 9 CFU day −1 mouse −1 ) used to establish the stable intestinal infection. In previous studies, a lower number of C. rodentium was inoculated to mice for the evaluation of preventive effect of LABs or other beneficial bacteria against the infection (Chen et al. 2005; Fanning et al. 2012; Jones and Knight 2012) . Therefore, KB290 would have a potential alleviation ability against C. rodentium infection and be meaningful as probiotics.
In conclusion, we found that KB290 intake could inhibit the proliferation of C. rodentium, especially in the early stage of infection, probably through the enhancement of TNF-α and IFN-γ production in the colon. Thus, our in vivo BLI approach will be useful for the evaluation of the protective effects of novel treatments, including probiotic LABs or antibiotics, against C. rodentium infection.
